MARIOTTINI, ALICE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.732
EU - Europa 3.135
AS - Asia 3.021
SA - Sud America 365
Continente sconosciuto - Info sul continente non disponibili 139
AF - Africa 124
OC - Oceania 34
Totale 10.550
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.640
RU - Federazione Russa 1.150
IT - Italia 1.048
CN - Cina 885
SG - Singapore 805
HK - Hong Kong 362
KR - Corea 288
BR - Brasile 286
VN - Vietnam 237
IE - Irlanda 187
FR - Francia 127
SE - Svezia 109
DE - Germania 103
IN - India 97
PL - Polonia 95
BD - Bangladesh 85
FI - Finlandia 84
NL - Olanda 75
JP - Giappone 57
CA - Canada 56
GB - Regno Unito 51
ID - Indonesia 45
JO - Giordania 41
AU - Australia 33
MA - Marocco 32
AR - Argentina 31
NG - Nigeria 27
ES - Italia 24
MX - Messico 23
TR - Turchia 23
CH - Svizzera 21
EC - Ecuador 19
IQ - Iraq 19
ZA - Sudafrica 19
IR - Iran 17
CI - Costa d'Avorio 13
EG - Egitto 12
UA - Ucraina 12
AT - Austria 9
CO - Colombia 9
PH - Filippine 9
UZ - Uzbekistan 9
MY - Malesia 8
BJ - Benin 7
PK - Pakistan 7
SA - Arabia Saudita 7
KE - Kenya 6
LV - Lettonia 5
PY - Paraguay 5
VE - Venezuela 5
DZ - Algeria 4
LT - Lituania 4
UY - Uruguay 4
CL - Cile 3
GR - Grecia 3
HN - Honduras 3
HU - Ungheria 3
KZ - Kazakistan 3
MK - Macedonia 3
SK - Slovacchia (Repubblica Slovacca) 3
TN - Tunisia 3
BY - Bielorussia 2
CR - Costa Rica 2
CZ - Repubblica Ceca 2
IL - Israele 2
JM - Giamaica 2
KG - Kirghizistan 2
LB - Libano 2
LI - Liechtenstein 2
NO - Norvegia 2
NP - Nepal 2
OM - Oman 2
PE - Perù 2
RO - Romania 2
AE - Emirati Arabi Uniti 1
AL - Albania 1
AZ - Azerbaigian 1
BE - Belgio 1
BG - Bulgaria 1
BH - Bahrain 1
BO - Bolivia 1
CY - Cipro 1
DK - Danimarca 1
DO - Repubblica Dominicana 1
ET - Etiopia 1
GD - Grenada 1
GE - Georgia 1
GT - Guatemala 1
IM - Isola di Man 1
IS - Islanda 1
KW - Kuwait 1
LA - Repubblica Popolare Democratica del Laos 1
LC - Santa Lucia 1
MQ - Martinica 1
NZ - Nuova Zelanda 1
PA - Panama 1
PT - Portogallo 1
RS - Serbia 1
SI - Slovenia 1
XK - ???statistics.table.value.countryCode.XK??? 1
Totale 10.412
Salva come PNG Salva come JPEG
Città #
Santa Clara 1.089
Singapore 623
Ashburn 532
Hong Kong 322
Hefei 309
Seoul 287
San Jose 232
Milan 231
Dublin 187
Beijing 135
Chandler 112
Fairfield 99
Florence 92
Ho Chi Minh City 91
Los Angeles 89
Rome 88
Warsaw 84
Kent 82
Council Bluffs 73
Lauterbourg 64
Buffalo 58
Tokyo 55
Hanoi 54
Munich 51
Moscow 50
Altamura 45
Dallas 45
Lawrence 45
The Dalles 44
Seattle 40
Mumbai 39
Boston 38
Paris 35
São Paulo 34
Wilmington 33
Cambridge 32
Jakarta 32
Lappeenranta 32
Woodbridge 32
New York 31
Princeton 31
Houston 30
Turku 28
Melbourne 27
Abuja 26
Naples 26
Casablanca 25
Helsinki 24
Shanghai 24
Frankfurt am Main 22
Chicago 21
Turin 21
Bengaluru 18
Bologna 18
Clifton 18
Orem 16
Da Nang 14
Modena 14
Abidjan 13
Chennai 13
Johannesburg 13
Rio de Janeiro 13
West Jordan 13
Catania 12
Hamburg 12
Palermo 12
Toronto 12
Bern 11
Guangzhou 11
London 11
Barcelona 10
Brooklyn 10
Dearborn 10
Genoa 10
Istanbul 10
Trieste 10
Atlanta 9
Medford 9
Quito 9
San Diego 9
Stockholm 9
Amsterdam 8
Belo Horizonte 8
Boardman 8
Cairo 8
Gdansk 8
Pune 8
Venice 8
Verona 8
Ann Arbor 7
Cotonou 7
Denver 7
Manchester 7
Miano 7
Montreal 7
Norwalk 7
Ottawa 7
Porto Alegre 7
Tashkent 7
Tehran 7
Totale 6.441
Salva come PNG Salva come JPEG
Nome #
K index improves MS diagnosis and supports the differential diagnosis between MS and MS-like syndromes. 445
Disease reactivation following fingolimod withdrawal in multiple sclerosis: Two case reports. 230
The TCR Repertoire Reconstitution in Multiple Sclerosis: Comparing One-Shot and Continuous Immunosuppressive Therapies 223
Safety and efficacy of autologous hematopoietic stem cell transplantation following natalizumab discontinuation in aggressive Multiple Sclerosis 216
Spinal cord size as promising biomarker of disability outcomes after hematopoietic stem cell transplantation in multiple sclerosis 202
Clinical characteristics predicting relapses following disease modifying therapies discontinuation in multiple sclerosis: a monocentric cohort study 202
Effect of the COVID-19 pandemic on disease activity in multiple sclerosis patients treated with hematopoietic stem cell transplantation 201
Early Morbidity of Autologous Haematopoietic Stem Cell Transplantation in Multiple Sclerosis- A Real World Experience 197
Safety and effectiveness of the booster dose of mRNA COVID-19 vaccines in people with multiple sclerosis: A monocentric experience 194
Clinical and paraclinical findings in a case series of MOGAD: Exploring the presence of perivenular brain white matter lesions 189
Effect of disease-modifying treatments on antibody-mediated response to anti- COVID19 vaccination in people with multiple sclerosis 189
Safety and tolerability of SARS-Cov-2 vaccination in patients with myasthenia gravis: A multicenter experience 188
Neuropsychological assessment in aggressive multiple sclerosis treated with stem cell transplantation 183
Successful switch to ofatumumab after liver injury associated with ocrelizumab treatment in multiple sclerosis: a case report 175
Impact of autologous haematopoietic stem cell transplantation on disability and brain atrophy in secondary progressive multiple sclerosis 172
Intermediate-Intensity Autologous Hematopoietic Stem Cell Transplantation Reduces Serum Neurofilament Light Chains and Brain Atrophy in Aggressive Multiple Sclerosis. 172
Leptomeningeal enhancement in multiple sclerosis: a focus on patients treated with hematopoietic stem cell transplantation 171
Acute unilateral sixth cranial nerve palsy and headache as initial manifestations of carcinomatous meningitis. 171
Severe disease reactivation in two multiple sclerosis patients after natalizumab withdrawal was not halted by monthly administrations of cyclophosphamide - two case reports 171
Anti-SARS-Cov2 vaccination at the time of the COVID-19 pandemic: suspected adverse events reporting is the milestone of post-marketing surveillance 170
Investigating Serum sHLA-G Cooperation With MRI Activity and Disease-Modifying Treatment Outcome in Relapsing-Remitting Multiple Sclerosis 166
Efficacy of autologous hematopoietic stem cell transplantation in secondary progressive Multiple sclerosis 164
Cost and effectiveness of autologous haematopoietic stem cell transplantation and high-efficacy disease-modifying therapies in relapsing–remitting multiple sclerosis 163
Autologous hematopoietic stem cell transplantation versus low-dose immunosuppression in secondary-progressive multiple sclerosis 161
Evaluation of dimethyl fumarate efficacy and safety in patients with relapsing remitting multiple sclerosis switching from other treatments 160
Autologous Hematopoietic Stem Cell Transplantation in Active Multiple Sclerosis: A Real-world Case Series 160
Reconstitution of natural or vaccination-driven immunity after aHSCT in multiple sclerosis 158
Case report: 3D intracranial vessel wall MRI in Susac syndrome: potential relevance for diagnosis and therapeutic management 156
Hematopoietic Stem Cell Transplantation in People With Active Secondary Progressive Multiple Sclerosis 153
Sustained disease remission in multiple sclerosis after autologous haematopoietic stem cell transplantation. The Italian experience 152
Disease Modifying Strategies in Multiple Sclerosis: New Rays of Hope to Combat Disability? 150
Comparative long term efficacy of beta interferons and azathioprine in relapsing-remitting Multiple sclerosis: single center retrospective 25 year evaluation 150
COVID-19 in patients with aggressive MS treated with aHSCT: a multi-center study 147
Incidence of malignant neoplasms and mortality in people affected by multiple sclerosis in the epoch of disease-modifying treatments: a population-based study on Tuscan residents 146
Sustained disease remission after discontinuation of disease modifying treatments in relapsing-remitting multiple sclerosis. 142
CNS inflammation during relapsing remitting multiple sclerosis (RRMS): a molecular and cellular analysis of ex vivo CSF T lymphocyte expansions 141
Real Life comparative evaluation of dimethyl fumarate efficacy and tolerability in relapsing remitting multiple sclerosis patients switching from other treatments 141
Impact of autologous haematopoietic stem cell transplantation on fertility in aggressive multiple sclerosis 139
Management of viral reactivation in multiple sclerosis patients after autologous transplantation with BEAM/ATG conditioning regimen 137
Antibody-mediated cell depletion therapies in multiple sclerosis 137
Hematopoietic Stem Cell Transplantation for the Treatment of Autoimmune Neurological Diseases: An Update 137
Prevalence of disability improvement as a potential outcome for multiple sclerosis trials 134
Challenges in Diagnosis of COVID-19 Pneumonia under Ocrelizumab and De-Risking Strategies in Multiple Sclerosis—The Elephant Is (Still) in the Room 131
Long-Term Clinical Outcomes of Hematopoietic Stem Cell Transplantation in Multiple Sclerosis 129
Immunosenescence and Autoimmunity: Exploiting the T-Cell Receptor Repertoire to Investigate the Impact of Aging on Multiple Sclerosis 129
Haematopoietic Stem Cell Transplantation for the Treatment of Multiple Sclerosis: Recent Advances 127
Soluble factor profile in Natalizumab treated MS patients: increased Th1 promoting factors and sHLAg 122
Exploring the therapeutic potential of autologous hematopoietic stem cell transplantation in progressive multiple sclerosis—a systematic review 121
intermediate intensity regimen in autologous HSCT for severe Multiple Sclerosis: a a large, single center experience 121
Intermediate intensity regimen in autologous HSCT for severe multiple sclerosis: a large, single center experience 120
Purely myeloablative conditioning regimen in aggressive multiple sclerosis: two case reports 119
Magnetic Resonance intracranial Vessel Wall Imaging (VWI) in Susac Syndrome: potential relevance for diagnosis and therapeutic management. 118
Autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK: A 20‐year retrospective analysis of activity and haematological outcomes from the British Society of Blood and Marrow Transplantation and Cellular Therapy (BSBMTCT) 117
Immune cell reconstitution following autologous hematopoietic stem cell transplantation in multiple sclerosis 116
Impact of new DMAs on the safety profile of patients undergoing autologous haematopoietic stem cell transplantation for Multiple Sclerosis 115
Relevance of Pathogenetic Mechanisms to Clinical Effectiveness of B-Cell-Depleting Monoclonal Antibodies in Multiple Sclerosis 113
Safety profile of autologous haematopoietic stem cell transplantation following natalizumab therapy in aggressive forms of multiple sclerosis 113
The role of chemotherapy in hematopoietic stem cell transplantation for autoimmune disorders: From lymphoablative to myeloablative conditioning protocols 110
Should autologous hematopoietic stem cell transplantation be offered as a first-line disease modifying therapy to patients with multiple sclerosis? 104
Preface 104
Low positive predictive value of Multiple Sclerosis diagnostic criteria in demyelinating syndromes with red flags of better explanation. 103
Thymic hyperplasia after autologous hematopoietic stem cell transplantation in multiple sclerosis: a case series 102
Haematopoietic Stem Cell Transplantation for Multiple Sclerosis: Current Status 99
Comparative efficacy of subcutaneous versus intravenous natalizumab on annualized relapse rate: a post-hoc analysis of the REFINE study 98
Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder — recommendations from ECTRIMS and the EBMT 97
Non-inferiority analysis of subcutaneous versus intravenous 300 mg monthly natalizumab administration: A post hoc analysis of the REFINE study 95
Effectiveness of Autologous Hematopoietic Stem Cell Transplantation versus Alemtuzumab and Ocrelizumab in Relapsing Multiple Sclerosis: A Single Center Cohort Study 91
CD20+ T Cells in Multiple Sclerosis: From Pathogenesis to Treatment-Induced Depletion 90
Aggressive MS and Autologous HSCT: A review on behalf of the Autoimmune Diseases Working Party of the European Society for Blood and Marrow Transplantation 84
Autologous haematopoietic stem cell transplantation affects long-term progression independent of relapse activity in aggressive multiple sclerosis: a comparative matched study 66
BEAM/ATG or cyclophosphamide/ATG as conditioning regimen in autologous haemopoietic stem cell transplantation for multiple sclerosis: a retrospective analysis of the EBMT autoimmune diseases working party 35
Should autologous HSCT be a first-line option in highly active MS: YES 34
Cell phenotype classification by NMR spectroscopy of intact cell lines 34
Real-world effectiveness of autologous haematopoietic stem cell transplantation for multiple sclerosis in the UK 28
Phenotype Classification of Intact Cells by NMR Spectroscopy through Machine Learning Approaches 10
Totale 10.550
Salva come PNG Salva come JPEG
Categoria #
all - tutte 30.739
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 30.739
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/2022205 2 15 8 9 2 8 5 33 18 7 32 66
2022/2023683 44 112 45 34 35 126 104 36 102 1 27 17
2023/2024631 16 75 69 35 53 47 24 106 29 66 77 34
2024/20253.545 126 327 201 503 828 561 109 230 145 96 167 252
2025/20264.907 547 666 609 523 429 144 517 192 261 309 215 495
2026/2027181 181 0 0 0 0 0 0 0 0 0 0 0
Totale 10.550